Apogee Enterprises increased its fiscal 2027 adjusted earnings forecast following a 9.2% rise in second-quarter net sales to $391.1 million, boosted by the Kalwall acquisition, pricing, and product mix. The company raised its adjusted diluted EPS guidance to $3.00-$3.40 and net sales outlook to $1.46-$1.50 billion. Operating income grew 24.5% to $33.5 million with margin improvements, while adjusted EBITDA rose 11.7% to $49.5 million. Despite a 5.4% drop in net earnings due to lower volume and higher costs, Apogee's strategic acquisitions and strong backlog position it well for growth. Shares rose 18% on the news.
Apogee Enterprises raised its fiscal 2027 adjusted diluted EPS guidance to a range of $3.00 to $3.40 following a 9.2% increase in second-quarter net sales to $391.1 million. For readers following the Industrials sector, here is Pluang's market snapshot as of Oct 06, 2026 22:52 WIB: out of 93 priced US Industrials stocks, 71 rose and 21 fell. Notable movers include Modine Manufacturing Company (MOD) at USD 192.00 with a 4.97% gain and a typical hold time of 32 days, Redwire Corporation (RDW) at USD 10.94 up 4.89% with 18 days hold, and MasTec Inc (MTZ) at USD 229.54 rising 4.62% with 24 days hold time.
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...
